iwAL 2022 Session III: novel targets, combinations and treatment strategies in AML
VJHemOnc Podcast
00:00
Exploring Primary Endpoints for TP53 Mutant Patients in AML
This chapter questions the importance of using complete remission rate (CR) as the primary endpoint for TP53 mutant patients in AML studies and suggests that overall survival (OS) may be a more relevant endpoint. Previous studies that showed an increase in CR rate but no benefit in OS are mentioned, and the need to explore early predictors such as VAF clearance is suggested.
Transcript
Play full episode
